Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Rounds Up $30 Million

NEW YORK, Jan. 27-Perlegen Sciences said today that it had closed a private placement of Series C Preferred Stock worth $30 million.

 

The round was led by Maverick Capital and included both new and repeat investors, among them Eli Lilly, Vulcan Ventures, Unilever Technology Ventures and SB Life Science Ventures.

 

Perlegen is an Affymetrix spinoff. It is based in Mountain View, Calif.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more